Company Overview of Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc. develops products to ameliorate the cause and symptoms associated with urological ailments. Its products include URG101, a proprietary combination therapy product that has completed a Phase II double blinded, placebo controlled, and multi-center trial for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS); and URG501, an oral pentosan polysulfate sodium therapy, which is in pre-clinical stage for the treatment of IC/BPS. The company is based in North Brunswick, New Jersey.
Technology Center of New Jersey
675 Highway One B-206
North Brunswick, NJ 08902
Key Executives for Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Urigen Pharmaceuticals, Inc., please visit www.urigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.